Recent publications

  1. Meulendijks D, Lassen U, Siu LL,  Huitema ADR. Karanikas V, Mau-Sorensen M, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, Bottino D, Zhong H, Roessler M, Vega-Harring SM, Jarutat T, Geho D, Wang K, DeMario M, Goss GD, Schellens JHM. Exposure and Tumor Fn14 expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-positive Solid Tumors. Clin Cancer Res (in press)   

  2. Meulendijks D, Jacob W Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, Langenberg MHG, Fleitas T, Cervantes A, De Jonge MJ, Sleijfer S, Mau Soerensen M, Thomas M, Ceppi M, Meneses-Lorente M, James I, Adessi C,  Michielin F, Abiraj K, Bossenmaier B, Schellens JHM, Weisser M, Lassen UN. First-in-human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-positive Solid Tumors. Clin Cancer Res (in press)

  3. Alanin MC, Klausen C, Cayé-Thomasen P, Thomsen C, Lassen U,  Mau-Sørensen M, Hofland KF. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series. International Journal of Neuroscience (in press)

  4. Persson M, Nedergaard M, Brandt-Larsen M, Skovgaard D, Jørgensen JT, Michaelsen SR, Madsen J, Lassen U, Poulsen HS, Kjaer A. uPAR is a Promising New Imaging Biomarker in Glioblastoma. J Nucl Med. 2015 Oct 1 [Epub ahead of print] 

  5. Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Boisserie F, Lestini B, Schostack K, Meresse V, Tabernero J. First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. Target Oncol. 2015 Aug 27. [Epub ahead of print] 

  6. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19. ​

  7. Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2015 Aug 5. [Epub ahead of print]

  8. ​Grunnet M, Christensen IJ, Lassen U, Jensen LH, Lydolph M, Knox JJ, McNamara MG, Jitlal M, Wasan H, Bridgewater J, Valle JW, Mau-Sorensen M. Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. Eur J Cancer. 51:1381-8, 2015.

  9. Mau-Sørensen M, Dittrich C, Dienstmann R, Lassen U, Büchler W, Martinius H, Tabernero J. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. Cancer Chemother Pharmacol. 2015 May;75(5):1065-73. doi: 10.1007/s00280-015-2728-5. Epub 2015 Mar 27. PubMed PMID: 25814216.

  10. Nedergaard MK, Michaelsen SR, Urup T, Broholm H, El Ali H, Poulsen HS, Stockhausen MT, Kjaer A, Lassen U. 18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma. PLoS One. 2015 Feb 13;10(2):e0115315. doi: 10.1371/journal.pone.0115315. eCollection 2015. PubMed PMID: 25680186; PubMed Central PMCID: PMC4332497.

  11. Lassen U, Chinot OL, McBain C, Mau-Sørensen M, Larsen VA, Barrie M, Roth P, Krieter O, Wang K, Habben K, Tessier J, Lahr A, Weller M. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro Oncol. 2015 Feb 9. pii: nov019. [Epub ahead of print] PubMed PMID: 25665807.

  12. El-Galaly TC, Bilgrau AE, de Nully Brown P, Mylam KJ, Ahmad SA, Pedersen LM, Gang AO, Bentzen HH, Juul MB, Bergmann OJ, Pedersen RS, Nielsen BJ, Johnsen HE, Dybkaer K, Bøgsted M, Hutchings M. A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. Br J Haematol. 2015 May;169(3):435-44. doi: 10.1111/bjh.13316. Epub 2015 Feb 23. PubMed PMID: 25709094.

  13. El-Galaly TC, Hutchings M. Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies. Cancer Treat Res. 2015;165:125-46. doi: 10.1007/978-3-319-13150-4_5. Review. PubMed PMID: 25655608.

  14. Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, Lassen U, Mau-Sorensen M, Hofland KF. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol. 2014 Nov 25. [Epub ahead of print] PubMed PMID: 25421643.

  15. Nielsen FC, Lassen U. [The genome and cancer treatment.]. Ugeskr Laeger. 2014 Nov 10;176(46). pii: V07140419. Danish. PubMed PMID: 25394934.

  16. Lassen UN, Meulendijks D, Siu LL, Karanikas V, Mau-Sorensen M, Schellens JH, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, Bottino D, Zhong H, Roessler M, Vega-Harring SM, Jarutat T, Geho D, Wang K, DeMario M, Goss GD. A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers. Clin Cancer Res. 2015 Jan 15;21(2):258-66. doi: 10.1158/1078-0432.CCR-14-1334. Epub 2014 Nov 11. PubMed PMID: 25388164.

  17. Hansson M, Gimsing P, Badros A, Niskanen TM, Nahi H, Offner F, Salomo M, Sonesson E, Mau-Sorensen M, Stenberg Y, Sundberg A, Teige I, Van Droogenbroeck J, Wichert S, Zangari M, Frendeus B, Korsgren M, Poelman M, Tricot G. A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2015 Feb 24. [Epub ahead of print] PubMed PMID: 25712687

  18. Grunnet M, Calatayud D, Schultz NA, Hasselby JP, Mau-Sørensen M, Brünner N, Stenvang J. TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas. Scand J Gastroenterol. 2015 Apr;50(4):485-94. doi: 10.3109/00365521.2014.980318. Epub 2015 Jan 23. PubMed PMID: 25615400.

  19. Poulsen HS, Urup T, Michaelsen SR, Staberg M, Villingshøj M, Lassen U. The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Manag Res. 2014 Sep 26;6:373-87. doi: 10.2147/CMAR.S39306. eCollection 2014. Review.
    PubMed PMID: 25298738; PubMed Central PMCID: PMC4186574.

  20. Tuxen IV, Jønson L, Santoni-Rugiu E, Hasselby JP, Nielsen FC, Lassen U. Personalized oncology: genomic screening in phase 1. APMIS. 2014 Aug;122(8):723-33. doi: 10.1111/apm.12293. Review. PubMed PMID: 25046202.

  21. Nedergaard MK, Kristoffersen K, Michaelsen SR, Madsen J, Poulsen HS, Stockhausen MT, Lassen U, Kjaer A. The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts. PLoS One. 2014 Jun 11;9(2):e100009. doi: 10.1371/journal.pone.0100009. eCollection 2014. PubMed PMID: 24918622; PubMed Central PMCID: PMC4053391.

  22. Grunnet M, Christensen IJ, Lassen U, Jensen LH, Lydolph M, Lund IK, Thurison T, Høyer-Hansen G, Mau-Sørensen M. Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients. Clin Biochem. 2014 May;47(7-8):599-604. doi: 10.1016/j.clinbiochem.2014.01.030. Epub 2014 Feb 12. PubMed PMID: 24530340.

  23. Hofland KF, Hansen S, Sorensen M, Engelholm S, Schultz HP, Muhic A, Grunnet K, Ask A, Costa JC, Kristiansen C, Thomsen C, Poulsen HS, Lassen U. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. Acta Oncol. 2014 Jul;53(7):939-44. doi: 10.3109/0284186X.2013.879607. Epub 2014 Jan 23. PubMed PMID: 24456504.

  24. Mylam KJ, Kostakoglu L, Hutchings M, Coleman M, Lamonica D, Czuczman MS, Diehl LF, Nielsen AL, Jensen P, Loft A, Hendel HW, Iyer V, Leppä S, Jyrkkiö S, Holte H, Eriksson M, Gillstrøm D, Hansen PB, Seppänen M, Hjorthaug K, Brown PD, Pedersen LM. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Leuk Lymphoma. 2014 Nov 20:1-8. [Epub ahead of print] PubMed PMID: 25330442.

  25. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014 Sep 20;32(27):3048-58. PubMed PMID: 25113771.

  26. Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, Loft A, Specht L, Lamonica D, Czuczman MS, Nanni C, Zinzani PL, Diehl L, Stern R, Coleman M. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. J Clin Oncol. 2014 Sep 1;32(25):2705-11. doi: 10.1200/JCO.2013.53.2838. Epub 2014 Jul 28. PubMed PMID: 25071108.

  27. Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. doi: 10.1200/JCO.2013.51.9298. Epub 2014 Mar 17. PubMed PMID: 24637998.

  28. El-Galaly TC, Mylam KJ, Bøgsted M, Brown P, Rossing M, Gang AO, Haglund A, Arboe B, Clausen MR, Jensen P, Pedersen M, Bukh A, Jensen BA, Poulsen CB, d'Amore F, Hutchings M. Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. Am J Hematol. 2014 Jun;89(6):575-80. doi: 10.1002/ajh.23688. Epub 2014 Feb 24. PubMed PMID: 24493389.

  29. El-Galaly TC, Hutchings M, Mylam KJ, Brown Pde N, Bukh A, Johnsen HE, Kamper P, Loft A, Iyer V, Gormsen LC, Nielsen AL, Bøgsted M, d'Amore F. Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. Leuk Lymphoma. 2014 Oct;55(10):2349-55. doi:10.3109/10428194.2013.875169. Epub 2014 Feb 24. PubMed PMID: 24354682.

  30. Mylam KJ, El-Galaly TC, Hutchings M, Brown P, Himmelstrup B, Gerke O, Gillstrøm D, Sillesen IB, Munksgaard L, Pedersen BB, Christiansen I, Jensen P, Nielsen AL, Pedersen LM. Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. Leuk Lymphoma. 2014 Jul;55(7):1563-9. doi: 10.3109/10428194.2013.850165. Epub 2013 Nov 14. PubMed PMID: 24144339.

  31. Lassen U, Sorensen M, Gaziel TB, Hasselbalch B, Poulsen HS. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res. 2013 Apr;33(4):1657-60. PubMed PMID: 23564811.

  32. Spindler KL, Sorensen MM, Pallisgaard N, Andersen RF, Havelund BM, Ploen J, Lassen U, Jakobsen AK. Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. Acta Oncol. 2013 Jun;52(5):963-70. doi: 10.3109/0284186X.2013.776175. Epub 2013 Mar 20. PubMed PMID: 23514584.​
Responsible editor